Phosphate Binder Use Has Declined Over the Past Two Years in the U.S. Dialysis Setting, While Sensipar Use in Hemodialysis has Declined Since Last Year

EXTON, Pa., June 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the use of phosphate binders in the U.S. has declined in both the hemodialysis and peritoneal dialysis setting over the past two years.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The ChartTrends: Bone and Mineral Metabolism in Dialysis (U.S.) 2013 report, the third ChartTrends dialysis report that has published since the dialysis bundle legislation was implemented in January 2011, finds that physicians are also initiating phosphate binders at higher serum phosphorous levels compared to last year. In addition, a significantly higher percentage of patient charts indicate that cost and the belief that phosphorous is low in the priority of treatment as two reasons for non-binder use compared to 2012.

The report also finds that Sanofi's sevelamer (Renagel, Renvela) is the market share leader in the dialysis patient population, with little change in share amongst the other binder brands compared to last year, with the exception of a decline in the use of calcium acetate.

Patients on non-calcium based binders (particularly Shire's Fosrenol) are more likely to be on Amgen's Sensipar compared to those on calcium-based binders, particularly calcium acetate.  From 2012 to 2013, use of Sensipar appears to be declining in the hemodialysis patient population.

"Despite the delay in the inclusion of orals in the dialysis bundle, we are starting to see changes in the dialysis setting likely driven by increased scrutiny and awareness of the total costs of treatment," said BioTrends Director Rob Dubman. "For example, we are now finding a rise in the use of nutritional Vitamin D and less use of AbbVie's Zemplar compared with 2012."

ChartTrends: Bone and Mineral Metabolism in Dialysis (U.S.) 2013 is a syndicated report series, in which 251 U.S. nephrologists provided patient chart data on 1,014 dialysis patients in the United States to uncover the actual management related to bone and mineral metabolism. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables, help define patient types and identify therapy triggers. The study also evaluates referral patterns, co-morbidities, concomitant medications, blood transfusions, hospitalizations and a host of other patient demographics and laboratory data.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
[email protected]  

SOURCE BioTrends Research Group